|Day Low/High||2.13 / 2.25|
|52 Wk Low/High||1.74 / 3.15|
Management to be joined by external guest speaker to review imetelstat data from IMerge to be presented at the 59th American Society of Hematology Annual Meeting and Exposition
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
Expanded Part 1 of IMerge is Open for Patient Enrollment
Geron and Endo and were among the biotech stock movers on Aug. 1.
Conference Call Scheduled for 8:00 a.m. ET on Tuesday, August 1
Investors eyeing a purchase of Geron Corp. stock, but tentative about paying the going market price of $2.96/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Investors in Geron Corp. saw new options become available this week, for the December 15th expiration.
OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.
Innoviva, Akebia Therapeutics and Geron were among the biotech stock movers in premarket trading on Tuesday.
Conference Call Scheduled for 4:30 p.m. ET Today, March 1
Investors in Geron Corp. saw new options become available this week, for the September 15th expiration.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.